Protective role of melatonin in liver damage

Current Pharmaceutical Design

Volumn 20, Issue 30, 2014, Pages 4828-4833

  Chojnacki, Cezary ^a   Walecka Kapica, Ewa ^a   Romanowski, Marek ^a   Chojnacki, Jan ^a   Klupinska, Grazyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Hepatic encephalopathy; Liver cirrhosis; Liver damage; Melatonin; Steatohepatitis

Indexed keywords

MELATONIN; TRYPTOPHAN; ANTIOXIDANT; REACTIVE OXYGEN METABOLITE;

ALCOHOL LIVER DISEASE; ARTICLE; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; LIVER DISEASE; LIVER INJURY; LIVER PROTECTION; LIVER RESECTION; NONHUMAN; PRIORITY JOURNAL; DETOXIFICATION; HEPATIC ENCEPHALOPATHY; LIVER CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL TECHNIQUE; LIVER DISEASES; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

HUMANS; LIVER DISEASES; MELATONIN; REACTIVE OXYGEN SPECIES;

EID: 84906215030     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666131119102155     Document Type: Article

References (124)

1. Lerner AB, Case JD, Lee TH, Mori W. Isolation of melatonin, the pineal factor, that lightens melanocytes. J Am Chem Sci 1958; 80: 2587-2592.
2. Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals Re-cept 2001; 10: 350-366
3. Velarde E, Cerdá-Reverter JM, Alonso-Gómez AL, Sánchez E, Isorna E, Delgado MJ. Melatonin-synthesizing enzymes in pineal, retina, liver, and gut of the goldfish (Carassius): mRNA expression pattern and regulation of daily rhythms by lighting conditions. Chronobiol Int 2010; 27: 1178-1201.
4. Shimozuma M, Tokuyama R, Tatehara S, et al. Expression and cellular localizaion of melatonin-synthesizing enzymes in rat and human salivary glands. Histochem Cell Biol 2011; 135: 389-396.
5. García-Marín R, de Miguel M, Fernández-Santos JM, et al. Melatonin-synthesizing enzymes and melatonin receptor in rat thyroid cells. Histol Histopathol 2012; 27: 1429-1438.
6. Itoh MT, Ishizuka B, Kuribayashi Y, Amemiya A, Sumi Y. Melatonin, its precursors, and synthesizing enzyme activities in the human ovary. Mol Hum Reprod 1999; 5: 402-408.
7. Zagajewski J, Drozdowicz D, Brzozowska I, et al. Conversion L-tryptophan to melatonin in the gastrointestinal tract: the new high performance liquid chromatography method enabling simultaneous determination of six metabolites of L-tryptophan by native fluorescence and UV-VIS detection. J Physiol Pharmacol 2012; 63(6): 613-621.
8. Finocchiaro LM, Nahmod VE, Launay JM. Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes. Biochem J 1991; 280: 727-731.
9. Carrillo-Vico A, Guerrero JM, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
10. Piesiewicz A, Kedzierska U, Adamska I, et al. Pineal arylalky-lamine N-acetyltransferase (Aanat) gene expression as a target of inflammatory mediators in the chicken. Gen Comp Endocrinol 2012; 179: 143-151.
11. Klein DC. Arylalkylamine-N-acetyltransferase, "time enzyme". J Biol Chem 2007; 282: 4233-4237
12. Ferreira ZS, Fernandes PA, Duma D, Assreuy J, Avellar MC, Markus RP. Corticosterone modulates noradrenaline-induced melatonin synthesis through inhibition of nuclear factor kappa B. J Pineal Res 2005; 38: 182-188.
13. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? FEBS J 2006; 273: 2813-2838.
14. Ribelayga C, Pévet P, Simonneaux V. Adrenergic and peptidergic regulations of hydroxyindole-O-methyltransferase activity in rat pineal gland. Brain Res 1997; 777: 247-250.
15. Karasek M, Wihczyk K. Melatonin in humans. J Physiol Pharmacol 2006; 57: 19-39.
16. Lane EA, Moss HB. Pharmacokinetics of melatonin in man: first pass hepatic metabolism. J Clin Endocrinol Metab 1985; 61: 1214-1216.
17. Facciolá G, Hidestrand M, von Bahr C, Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 2001; 56: 881-888.
18. Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos 2005; 33: 489-494.
19. Hardeland R. Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005; 27: 119-130.
20. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42: 28-42.
21. Reiter RJ, Tan DX, Terron MP, Flores LJ, Czarnocki Z. Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 2007; 54: 1-9.
22. Rodriguez C, Mayo JC, Sainz RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
23. Tomás-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005; 39: 99-104.
24. Bettahi I, Pozo D, Osuna C et al. Melatonin reduces nitric oxide synthase activity in rat hypothalamus. J Pineal Res 1996; 20: 205-210.
25. Zhang H, Akbar M, Kim HY. Melatonin: an endogenous negative modulator of 12-lipoxygenation in the rat pineal gland. Biochem J 1999; 344: 487-493.
26. Messner M, Huether G, Lorf T et al. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69: 543-551.
27. Pääkkönen T, Mäkinen TM, Leppäluoto J et al. Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions. J Pineal Res 2006; 40: 110-115.
28. Baskett JJ, Cockrem JF, Antunovich TA. Sulphatoxymelatonin excretion in older people: relationship to plasma melatonin and renal function. J Pineal Res 1998; 24: 58-61.
29. Tan D, Manchester LC, Reiter RJ, Qi W, Hanes MA, Farley NJ. High physiological levels of melatonin in the bile of mammals. Life Sci 1999; 65: 2523-2529.
30. Messner M, Huether G, Lorf T, Ramadori G, Schwörer H. Presence of melatonin in the human hepatobiliary-gastrointestinal tract. Life Sci 2001; 69: 543-551.
31. Sanchez-Hidalgo M, de la Lastra CA, Carrascosa-Salmoral MP, et al. Age-related changes in melatonin synthesis in rat extrapineal tissues. Exp Gerontol 2009; 44: 328-334.
32. Velarde E, Cerdá-Reverter JM, Alonso-Gómez AL, Sánchez E, Isorna E, Delgado MJ. Melatonin-synthesizing enzymes in pineal, retina, liver, and gut of the goldfish (Carassius): mRNA expression pattern and regulation of daily rhythms by lighting conditions. ChronobiolInt 2010; 27: 1178-1201.
33. Nisembaum LG, Tinoco AB, Moure AL, Alonso Gómez AL, Delgado MJ, Valenciano AI. The arylalkylamine-N-acetyltrans-ferase (AANAT) acetylates dopamine in the digestive tract of goldfish: a role in intestinal motility. Neurochem Int 2013; 62: 873-880.
34. Venegas C, García JA, Escames G, et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res 2012; 52(2): 217-227.
35. Tan DX, Manchester LC, Reiter RJ, Qi WB, Karbownik M, Calvo JR. Significance of melatonin in antioxidative defense system: reactions and products. Biol Signals Recept 2000; 9(3-4): 137-159.
36. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36(1): 1-9.
37. Basile M, Romeo C, Gitto E, Spitz L, Pierro A, Eaton S. Melatonin protects from, but does not reverse, the effects of mediators of sepsis on liver bioenergetics. Pediatr Surg Int 2004; 20: 263-266.
38. Kus I, Ogeturk M, Oner H, Sahin S, Yekeler H, Sarsilmaz M. Protective effects of melatonin against carbon tetrachloride-induced hepatotoxicity in rats: a light microscopic and biochemical study. Cell Biochem Funct 2005; 23: 169-174.
39. Wang H, Wei W, Wang NP, et al. Melatonin ameliorates carbon tetrachloride-induced hepatic fibrogenesis in rats via inhibition of oxidative stress. Life Sci 2005; 77: 1902-1915.
40. Ebaid H, Bashandy SA, Alhazza IM, Rady A, El-Shehry S. Folic acid and melatonin ameliorate carbon tetrachloride-induced hepatic injury, oxidative stress and inflammation in rats. Nutr Metab (Lond) 2013; 10: 20.
41. Tahan V, Ozaras R, Canbakan B, et al. Melatonin reduces dimeth-ylnitrosamine-induced liver fibrosis in rats. J Pineal Res 2004; 37: 78-84.
42. Matsura T, Nishida T, Togawa A, et al. Mechanisms of protection by melatonin against acetaminophen-induced liver injury in mice. J Pineal Res 2006; 41: 211-219.
43. Cheshchevik VT, Dremza IK, Lapshina EA, Zabrodskaya SV, Kujawa J, Zavodnik IB. Corrections by melatonin of liver mito-chondrial disorders under diabetes and acute intoxication in rats. Cell Biochem Funct 2011; 29: 481-488.
44. El-Sokkary GH, Cuzzocrea S, Reiter RJ. Effect of chronic nicotine administration on the rat lung and liver: beneficial role of melatonin. Toxicology 2007; 239: 60-67.
45. Mercan S, Eren B. Protective role of melatonin supplementation against nicotine-induced liver damage in mouse. Toxicol Ind Health 2012; 14.
46. Sewerynek E, Melchiorri D, Reiter RJ, Ortiz GG, Lewinski A. Lipopolysaccharide-induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur J Pharmacol 1995; 293: 327-334.
47. Wang H, Wei W, Shen YX, et al. Protective effect of melatonin against liver injury in mice induced by Bacillus Calmette-Guerin plus lipopolysaccharide. World J Gastroenterol 2004; 10: 2690-2696.
48. Tuñón MJ, San Miguel B, Crespo I, et al. Melatonin attenuates apoptotic liver damage in fulminant hepatic failure induced by the rabbit hemorrhagic disease virus. J Pineal Res 2011; 50: 38-45.
49. Laliena A, San Miguel B, Crespo I, Alvarez M, González-Gallego J, Tuñón MJ. Melatonin attenuates inflammation and promotes regeneration in rabbits with fulminant hepatitis of viral origin. Pineal Res 2012; 53: 270-278.
50. Zaoualí MA, Reiter RJ, Padrissa-Altés S, et al. Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. J Pineal Res 2011; 50: 213-221.
51. Bülbüller N, Cetinkaya Z, Akkus MA, et al. The effects of melatonin and prostaglandin E1 analogue on experimental hepatic ischaemia reperfusion damage. Int J Clin Pract 2003; 57: 857-860.
52. Vairetti M, Ferrigno A, Bertone R, et al. Exogenous melatonin enhances bile flow and ATP levels after cold storage and reperfusion in rat liver: implications for liver transplantation. J Pineal Res 2005; 38: 223-230.
53. Kang JW, Koh EJ, Lee SM. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J Pineal Res 2011; 50: 403-411.
54. Ohta Y, Kongo M, Kishikawa T. Melatonin exerts a therapeutic effect on cholestatic liver injury in rats with bile duct ligation. J Pineal Res 2003; 34: 119-126.
55. Padillo FJ, Cruz A, Navarrete C, et al. Melatonin prevents oxidative stress and hepatocyte cell death induced by experimental cholestasis. Free Radic Res 2004; 38: 697-704.
56. Esrefoglu M, Gül M, Emre MH, Polat A, Selimoglu MA. Protective effect of low dose of melatonin against cholestatic oxidative stress after common bile duct ligation in rats. World J Gastroenterol 2005; 11: 1951-1956.
57. Aktas C, Kanter M, Erboga M, Mete R, Oran M. Melatonin attenuates oxidative stress, liver damage and hepatocyte apoptosis after bile-duct ligation in rats. Toxicol Ind Health 2012; 24.
58. Sahna E, Parlakpinar H, Vardi N, Cigremis Y, Acet A. Efficacy of melatonin as protectant against oxidative stress and structural changes in liver tissue in pinealectomized rats. Acta Histochem 2004; 106: 331-336.
59. Sallinen P, Saarela S, Ilves M, Vakkuri O, Leppäluoto J. The expression of MT1 and MT2 melatonin receptor mRNA in several rat tissues. Life Sci 2005; 76: 1123-1134.
60. Huang H, Yin R, Zhu J, et al. Exogenous melatonin ameliorates hepatic injury in a rat cardiopulmonary bypass model. Eur J Pharmacol 2008; 580: 416-424.
61. Letelier ME, Jara-Sandoval J, Molina-Berríos A, Faúndez M, Aracena-Parks P, Aguilera F. Melatonin protects the cytochrome P450 system through a novel antioxidant mechanism. Chem Biol Interact 2010; 185: 208-214.
62. Bicer M, Akil M, Avunduk MC, Kilic M, Mogulkoc R, Baltaci AK. Interactive effects of melatonin, exercise and diabetes on liver glycogen levels. Endokrynol Pol 2011; 62: 252-256.
63. Esrefoglu M, Iraz M, Ates B, Gul M. Melatonin and CAPE are able to prevent the liver from oxidative damage in rats: an ultrastructural and biochemical study. Ultrastruct Pathol 2012; 36: 171-178.
64. González MA, ContiniMdel C, Millen N, Mahieu ST. Role of melatonin in the oxidative damage prevention at different times of hepatic regeneration. Cell Biochem Funct 2012; 30: 701-708.
65. Korkmaz GG, Uzun H, Cakatay U, Aydin S. Melatonin ameliorates oxidative damage in hyperglycemia-induced liver injury. Clin Invest Med 2012; 35: E370-E377.
66. Manikonda PK, Jagota A. Melatonin adminisration differentially affects age-induced alterations in daily rhythms of lipid peroxidation and antioxidant enzymes in males rat liver. Biogerontology 2012; 13: 511-524.
67. Rodriguez-Reynoso S, Leal C, Portilla E, Olivares N, Muniz J. Effect of exogenous melatonin on hepatic energetic status during ischemia/reperfusion: possible role of tumor necrosis factor-alpha and nitric oxide. J Surg Res 2001; 100: 141-149.
68. Carrillo-Vico A, Lardone PJ, Nail L, et al. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 2005; 39: 400-408.
69. Mishra A, Paul S, Swarnakar S. Downregulation of matrix metallo-proteinase-9 by melatonin during prevention of alcohol-induced liver injury in mice. Biochimie 2011; 93: 854-866.
70. Tahan G, Akin H, Aydogan F, et al. Melatonin ameliorates liver fibrosis induced by bile-duct ligation in rats. Can J Surg 2010; 53: 313-318.
71. Hong RT, Xu JM, Mei Q: Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats. J Pineal Res 2011; 51: 1-16.
72. Venegas C, García JA, Doerrier C, et al. Analysis of the daily changes of melatonin receptors in the rat liver. J Pineal Res 2013; 54(3): 313-321.
73. Naji L, Carrillo-Vico A, Guerrero JM, Calvo JR. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci 2004; 74: 2227-2236.
74. Ishii H, Tanaka N, Kobayashi M, Kato M, Sakuma Y. Gene structures, biochemical characterization and distribution of rat melatonin receptors. J Physiol Sci 2009; 59: 37-47.
75. Schmidt R. Hepatoprotective actions of melatonin: Possible mediation by melatonin receptors. World J Gastroenterol 2010; 16: 6087-6097.
76. Mathes AM, Kubulus D, Waibel L et al. Selective activation of melatonin receptors with ramelteon improves liver function and hepatic perfusion after hemorrhagic shock in rat. Crit Care Med 2008; 36: 2863-2870.
77. Tomás-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005; 39: 99-104.
78. Rodriguez C, Mayo JC, Sainz RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9.
79. González MA, Contini Mdel C, Millen N, Mahieu ST. Role of melatonin in the oxidative damage prevention at different times of hepatic regeneration. Cell Biochem Funct 2012; 30: 701-708.
80. Mathes AM, Wolf B, Rensing H: Melatonin receptor antagonist luzindole is a powerful radical scavenger in vitro. J Pineal Res 2008; 45: 337-338.
81. Kim SH, Lee SM. Cytoprotective effects of melatonin against necrosis and apoptosis induced by ischemia/reperfusion injury in rat liver. J Pineal Res 2008; 44: 165-171.
82. Aravamudhan A, Ramos DM, Nip J, et al. Osteoinductive small molecules: growth factor alternatives for bone tissue engineering. Curr Pharm Des 2013; 19(19): 3420-3428.
83. Daniels WM, Reiter RJ, Melchiorri D, Sewerynek E, Pablos MI, Ortiz GG. Melatonin counteracts lipid peroxidation induced by carbon tetrachloride but does not restore glucose-6 phosphatase activity. J Pineal Res 1995; 19: 1-6.
84. Kim SJ, Reiter RJ, Rouvier Garay MV, Qi W, El Sokkary GH, Tan DX. 2-Nitropropane-induced lipid peroxidation: antitoxic effects of melatonin. Toxicology 1998; 130: 183-190.
85. Hu S, Yin S, Jiang X, Huang D, Shen G. Melatonin protects against alcoholic liver injury by attenuating oxidative stress, inflammatory response, and apoptosis. Eur J Pharmacol 2009; 616: 287-292.
86. Genç S, Gürdöl F, Oner-Iyidogan Y, Onaran I: The effect of melatonin administration on ethanol-induced lipid peroxidation in rats. Pharmacol Res 1998; 37: 37-40.
87. Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohe-patitis. Semin Liver Dis 2001; 21: 27-41.
88. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-330.
89. Gonciarz M, Gonciarz Z, Bielanski W, et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J Physiol Pharmacol 2010; 61: 705-710.
90. Cichoz-Lach H, Celinski K, Konturek PC, Konturek SJ, Slomka M. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol 2010; 61: 577-580.
91. Celinski K, Konturek PC, Slomka M, et al. Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. J Pineal Res 2009; 46: 408-414.
92. Iguchi H, Kato KI, Ibayashi H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab 1982; 54: 1025-1027.
93. Steindl PE, Finn B, Bendok B, Rothke S, Zee PC, Blei AT. Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Ann Intern Med 1995; 123: 274-277.
94. Steindl PE, Finn B, Bendok B, Rothke S, Zee PC, Blei AT. Changes in the 24-hour rhythm of plasma melatonin in patients with liver cirrhosis--relation to sleep architecture. Wien Klin Wo-chenschr 1997; 109: 741-746.
95. Montagnese S, Middleton B, Mani AR, Skene DJ, Morgan MY. Melatonin rhythms in patients with cirrhosis. Am J Gastroenterol 2010; 105(1): 220-222.
96. Zee PC, Mehta R, Turek FW, Blei AT. Portacaval anastomosis disrupts circadian locomotor activity and pineal melatonin rhythms in rats. Brain Res 1991; 560: 17-22.
97. Coy DL, Mehta R, Zee P, Salchli F, Turek FW, Blei AT. Portal-systemic shunting and the disruption of circadian locomotor activity in the rat. Gastroenterology 1992; 103: 222-228.
98. Ardizzi A, Grugni G, Saglietti G, Morabito F. Circadian rhythm of melatonin in liver cirrhosis. Minerva Med 1998; 89: 1-4.
99. Montagnese S, Middleton B, Mani AR, Skene DJ, Morgan MY. Sleep and circadian abnormalities in patients with cirrhosis: features of delayed sleep phase syndrome? Metab Brain Dis 2009; 24: 427-439.
100. Velissaris D, Karamouzos V, Polychronopoulos P, Karanikolas M. Chronotypology and melatonin alterations in minimal hepatic encephalopathy. J Circadian Rhythms 2009; 7: 1-6.
101. Cordoba J, Steindl P, Blei AT. Melatonin arrhythmia is corrected after liver transplantation. Am J Gastroenterol 2009; 104: 1862-1863.
102. J. Ducis, Effect of ammonia and R05-4864 on melatonin release in pineal. J Neurochem 1994: 62: A-37.
103. Chojnacki C, Romanowski M, Winczyk K, Blasiak J, Chojnacki J. Melatonin levels in serum and ascitic fluid of patients with hepatic encephalopathy. Gastroenterol Res Pract. 2012; 2012: 1-7.
104. Chojnacki C, Wachowska-Kelly P, Blasiak J, Reiter RJ, Chojnacki J. Melatonin secretion and metabolism in patients with hepatic encephalopathy. J Gastroenterol Hepatol 2013; 28: 342-347.
105. Klupihska G, Wisniewska-Jarosihska M, Harasiuk A, et al. Nocturnal secretion of melatonin in patients with upper digestive tract disorders. J Physiol Pharmacol 2006; 57 (Suppl 5): 41-50.
106. Komarov FI, Rapoport SI, Malinovskaia NK, Voznesenskaia LA, Vetterberg L. Melatonin: ulcer disease and seasons of the year. Klin Med 2013; 81: 17-21.
107. Boznahska P, Wichan P, Stepieh A, et al. 24-hour urinary 6-hydroxymelatonin sulfate excretion in patients with ulcerative colitis]. Pol Merkur Lekarski 2007; 22: 369-372.
108. Arendt J, Bhanji S, Franey C, Mattingly D. Plasma melatonin levels in anorexia nervosa. Br J Psychiatry 1992; 161: 361-364.
109. Berga SL, Mortola JF, Yen SS. Amplification of nocturnal mela-tonin secretion in women with functional hypothalamic amenor-rhea. J Clin Endocrinol Metab 1988; 66: 242-244.
110. Richey SM, Krystal AD. Pharmacological advances in the treatment of insomnia. Curr Pharm Des 2011; 17(15): 1471-1475.
111. Werbach MR. Melatonin for the treatment of gastroesophageal reflux disease. Altern Ther Health Med 2008; 14: 54-58.
112. Klupinska G, Poplawski T, Drzewoski J, et al. Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroen-terol 2007; 41: 270-274.
113. Celinski K, Konturek PC, Konturek SJ, et al. Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Heli-cobacter pylori infection in humans. J Physiol Pharmacol. 2011; 62: 521-526.
114. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2005; 22: 927-934.
115. Karakus E, Halici Z, Albayrak A, et al. Agomelatine: An antide-pressant with new potent hepatoprotective effects on paracetamol-induced liver damage in rats. Hum Exp Toxicol 2013 (in press).
116. McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S. The use of antidepressants in clinical practice: focus on agomelatine. Hum Psychopharmacol 2010; 25: 95-102.
117. Gonciarz M, Gonciarz Z, Bielanski W, et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol 2012; 63: 35-40.
118. Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39: 307-313.
119. Mowafi HA, Ismail SA. Melatonin improves tourniquet tolerance and enhances postoperative analgesia in patients receiving intravenous regional anesthesia. Anesth Analg 2008; 107(4): 1422-1426.
120. Yousaf F, Seet E, Venkatraghavan L, Abrishami A, Chung F. Efficacy and safety of melatonin as an anxiolytic and analgesic in the perioperative period: a qualitative systematic review of randomized trials. Anesthesiology 2010; 113: 968-976.
121. Liang R, Nickkholgh A, Hoffmann K, et al. Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation. J Pineal Res 2009; 46: 8-14.
122. Schemmer P, Nickkholgh A, Schneider H, et al. PORTAL: pilot study on the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection: a double-blind randomized placebo-controlled trial. BMC Surg 2008; 23; 8: 2-8.
123. Nickkholgh A, Schneider H, Sobirey M, et al. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res 2011; 50: 381-388.
124. Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res 2012; 52: 437-445.